Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Novel therapies for children with severe asthma
Top Ten Searches
hla beta 2 probiotics hypo allergenic scid urticaria aeroallergens asthma angioedema hivYour Article Summary
Human Neutrophils Coordinate Chemotaxis by Differential Activation of Rac1 and Rac2
Journal of Immunology, 08/20/09
Zhang H et al. – The authors propose a model to explain how human neutrophils kill invading microbes while limiting oxidative damage to the adjacent surrounding healthy tissue through the differential activation of Rac1 and Rac2 in response to different concentrations of chemoattractant.
Related Articles
Melanocortin peptides inhibit urate crystal-induced activation of phagocytic cells
Arthritis Research & Therapy, 10/12/09
Relevance Score: 91%
Lipoxin A4 Metabolites/Analogues from Two Commercial Sources have No Effects on TNF-alpha-mediated Priming or Activation through the Neutrophil Formyl Peptide Receptors
Scandinavian Journal of Immunology, 10/01/09
Relevance Score: 88%
Cystic fibrosis neutrophils have normal intrinsic reactive oxygen species generation
European Respiratory Journal, 10/23/09
Relevance Score: 87%
Pleiotropic effects of neutrophils on myocyte apoptosis and left ventricular remodeling during early volume overload
Journal of Molecular and Cellular Cardiology, 10/19/09
Relevance Score: 87%
Opening the flood-gates: how neutrophil-endothelial interactions regulate permeability
Trends in Immunology, 10/08/09
Relevance Score: 87%
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Prioritization of cancer antigens: keeping the target in sight
Expert Review of Vaccines, 12/02/09
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Clinical Cancer Research, 12/01/09
A High-Affinity Fully Human Anti–IL-6 mAb, 1339, for the Treatment of Multiple Myeloma
Clinical Cancer Research, 12/01/09
Sponsor
Article Search
Sponsor


See Latest Articles


